Literature DB >> 11223070

Development and applications of surface-linked single chain antibodies against T-cell antigens.

M D Griffin1, P O Holman, Q Tang, N Ashourian, U Korthäuer, D M Kranz, J A Bluestone.   

Abstract

In this report the use of surface-linkage to expand the potential experimental and therapeutic applications of single chain antibody (scFv) constructs is reviewed. A strategy for the generation and functional characterization of surface-linked scFvs that bind selectively to the T-cell proteins CD3epsilon, CD28, and CD152 (CTLA-4) is described in detail. Experimental examples are provided of the use of these constructs to study the positive and negative regulation of T-cell activation and to manipulate the in vivo immunogenicity of tumor cells. In addition, a novel system for Simultaneous T-cell Activation and Retroviral Transduction (START) is described in which retroviral packaging cells are rendered mitogenic for T lymphocytes by combined expression of surface-linked scFvs. Finally, the use of random mutagenesis and yeast surface display to increase the affinity and functional efficacy of scFv constructs is demonstrated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223070     DOI: 10.1016/s0022-1759(00)00344-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

Review 1.  Up against the wall: is yeast cell wall integrity ensured by mechanosensing in plasma membrane microdomains?

Authors:  Christian Kock; Yves F Dufrêne; Jürgen J Heinisch
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

Review 2.  Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

Authors:  Hélène Bour-Jordan; Jonathan H Esensten; Marc Martinez-Llordella; Cristina Penaranda; Melanie Stumpf; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

3.  Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.

Authors:  Brian T Fife; Matthew D Griffin; Abul K Abbas; Richard M Locksley; Jeffrey A Bluestone
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

4.  Ligation of cytotoxic T lymphocyte antigen-4 to T cell receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells.

Authors:  Jozsef Karman; Ji-Lei Jiang; Nathan Gumlaw; Hongmei Zhao; Juanita Campos-Rivera; Jose Sancho; Jinhua Zhang; Canwen Jiang; Seng H Cheng; Yunxiang Zhu
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

5.  Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.

Authors:  Jonas Persson; Ines Beyer; Roma Yumul; ZongYi Li; Hans-Peter Kiem; Steve Roffler; André Lieber
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

6.  A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT.

Authors:  Zhihao Fu; Hongchuan Liu; Lan Wang; Chuanfei Yu; Yalan Yang; Meiqing Feng; Junzhi Wang
Journal:  Acta Pharm Sin B       Date:  2021-09-17       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.